HemoShear Advances Human Relevant Science to Predict New Drug Safety
Friday, September 27, 2013
Posted by: Sherri Halloran
Safe, new life-saving drug therapies may flow faster to patients who
need them most, stimulated by a $1.6 million grant to HemoShear, LLC,
from a division of the U.S. National Institutes of Health (NIH).
HemoShear, LLC, a developer of advanced human-relevant systems for
applications in drug R&D.
The grant from NIH supports the
advancement of HemoShear's breakthrough technology, which leaps past
decades-old methods for determining safety and efficacy of new drug
candidates. In addition to the transformative human benefits of improved
drug therapies, HemoShear's technology could improve new drug
development success rates while saving hundreds of millions of dollars
for the pharmaceutical industry in costly, misguided decisions.
extensive data are impressive. This is a very challenging space, and I
have never before seen a technology that comes as close to replicating
human liver biology in the laboratory," said Dr. Gerald Fisher, a
HemoShear advisor and former senior vice president of Drug Safety at
According to the U.S. Food and Drug
Administration, liver toxicity is the most frequent cause of
discontinuation of clinical trials for new drugs. HemoShear's unique
science accurately replicates the conditions that human cells experience
in the body, avoiding unexpected drug toxicity findings in clinical
studies and improving confidence in advancing optimal drug candidates.
The Small Business Innovation Research Grant from the National Institute
of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of
NIH, is intended to demonstrate that the Company's advanced,
human-relevant science can predict the safety of new drug candidates
well before the costly clinical stages of drug development.
award is HemoShear's second phase II SBIR grant from NIH in three years,
demonstrating strong support by NIH and the scientific community for
HemoShear's science. HemoShear is already collaborating with a select
group of major pharmaceutical and biotechnology companies to assess the
efficacy of new drugs that target the liver and to understand unexpected
causes of toxicity.
"We are grateful for the support of our grant
application by senior pharmaceutical executives and scientists who are
actively seeking better systems with which to assess liver safety of
their drug candidates," said Dr. Ajit Dash, HemoShear's senior
scientific director who leads the liver systems development program.